Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LMNA | P02545 | 2/20 | 0.38 |
| ▸ | MEN1 | O00255 | 1/20 | 0.38 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.38 |
| ▸ | HRH1 | P35367 | 1/20 | 0.38 |
| ▸ | SCN1A | P35498 | 1/20 | 0.38 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.38 |
| ▸ | SCN2A | Q99250 | 1/20 | 0.38 |
| ▸ | SCN3A | Q9NY46 | 1/20 | 0.38 |
| ▸ | CHRM3 | P20309 | 2/20 | 0.37 |
| ▸ | KEAP1 | Q14145 | 1/20 | 0.37 |
| ▸ | NFE2L2 | Q16236 | 1/20 | 0.37 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.36 |
| ▸ | ATM | Q13315 | 1/20 | 0.36 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.36 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.35 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL10784340 | 0.90 | LMNA (0.40) | LMNAMEN1CYP2D6HRH1SCN1A | |
| SCHEMBL17914392 | 0.83 | HDAC4 (0.31) | — | |
| SCHEMBL8550117 | 0.80 | L3MBTL1 (0.39) | MEN1KMT2AL3MBTL1 | |
| SCHEMBL2738540 | 0.76 | FKBP1A (0.33) | — | |
| SCHEMBL28859583 | 0.75 | LMNA (0.35) | LMNAKEAP1NFE2L2SMN1; SMN2ATM | |
| SCHEMBL8745049 | 0.74 | SSTR4 (0.33) | — | |
| SCHEMBL17914413 | 0.73 | HTT (0.30) | — | |
| SCHEMBL2737103 | 0.73 | ACACB (0.35) | LMNAMEN1CYP2D6HRH1KMT2A | |
| SCHEMBL431383 | 0.72 | FKBP1A (0.32) | — | |
| SCHEMBL12891263 | 0.72 | FKBP1A (0.32) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 21 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-4690157-A | DERIVATIVES OF BUTYROLACTONE OR VALEROLACTONE; CIGARETTES | PHILIP MORRIS INCORPORATED (US) | 1987-09-01 | — | — | US | claimed |
| US-8586762-B2 | Process for producing fused imidazole compound, reformatsky reagent in stable form, and process for producing the same | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2013-11-19 | — | — | US | disclosed |
| US-8586762-B2 | Process for producing fused imidazole compound, reformatsky reagent in stable form, and process for producing the same | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2013-11-19 | — | — | US | disclosed |
| EP-1471056-B1 | PROCESS FOR PRODUCING FUSED IMIDAZOLE COMPOUND, REFORMATSKY REAGENT IN STABLE FORM, AND PROCESS FOR PRODUCING THE SAME | TAKEDA PHARMACEUTICAL (JP) | 2012-07-11 | — | — | EP | disclosed |
| US-20120077985-A1 | PROCESS FOR PRODUCING FUSED IMIDAZOLE COMPOUND, REFORMATSKY REAGENT IN STABLE FORM, AND PROCESS FOR PRODUCING THE SAME | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2012-03-29 | — | — | US | disclosed |
| US-20120077985-A1 | PROCESS FOR PRODUCING FUSED IMIDAZOLE COMPOUND, REFORMATSKY REAGENT IN STABLE FORM, AND PROCESS FOR PRODUCING THE SAME | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2012-03-29 | — | — | US | disclosed |
| US-20120077985-A1 | PROCESS FOR PRODUCING FUSED IMIDAZOLE COMPOUND, REFORMATSKY REAGENT IN STABLE FORM, AND PROCESS FOR PRODUCING THE SAME | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2012-03-29 | — | — | US | disclosed |
| US-8093403-B2 | Process for producing fused imidazole compound, reformatsky reagent in stable form, and process for producing the same | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2012-01-10 | — | — | US | disclosed |
| US-8093403-B2 | Process for producing fused imidazole compound, reformatsky reagent in stable form, and process for producing the same | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2012-01-10 | — | — | US | disclosed |
| US-8093403-B2 | Process for producing fused imidazole compound, reformatsky reagent in stable form, and process for producing the same | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2012-01-10 | — | — | US | disclosed |
| EP-2275411-A2 | Reformatsky Reagent in Stable Form and Process for Producing the Same | Takeda Pharmaceutical Company Limited (JP) | 2011-01-19 | — | — | EP | disclosed |
| US-20100105922-A1 | PROCESS FOR PRODUCING FUSED IMIDAZOLE COMPOUND, REFORMATSKY REAGENT IN STABLE FORM, AND PROCESS FOR PRODUCING THE SAME | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2010-04-29 | — | — | US | disclosed |
| US-20100105922-A1 | PROCESS FOR PRODUCING FUSED IMIDAZOLE COMPOUND, REFORMATSKY REAGENT IN STABLE FORM, AND PROCESS FOR PRODUCING THE SAME | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2010-04-29 | — | — | US | disclosed |
| US-20100105922-A1 | PROCESS FOR PRODUCING FUSED IMIDAZOLE COMPOUND, REFORMATSKY REAGENT IN STABLE FORM, AND PROCESS FOR PRODUCING THE SAME | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2010-04-29 | — | — | US | disclosed |
| US-7662974-B2 | reduction of carboxylic acid ester using metal hydride complexes and metal halides to form compounds such as ethyl (3S)-3-hydroxy-3-{6-[(methylamino)carbonyl]-2-naphthyl}-3-(1-trityl-1H-imidazol-4-yl)propanoate, used as lyase enzyme inhibitors | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2010-02-16 | — | — | US | disclosed |
| US-7662974-B2 | reduction of carboxylic acid ester using metal hydride complexes and metal halides to form compounds such as ethyl (3S)-3-hydroxy-3-{6-[(methylamino)carbonyl]-2-naphthyl}-3-(1-trityl-1H-imidazol-4-yl)propanoate, used as lyase enzyme inhibitors | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2010-02-16 | — | — | US | disclosed |
| US-7662974-B2 | reduction of carboxylic acid ester using metal hydride complexes and metal halides to form compounds such as ethyl (3S)-3-hydroxy-3-{6-[(methylamino)carbonyl]-2-naphthyl}-3-(1-trityl-1H-imidazol-4-yl)propanoate, used as lyase enzyme inhibitors | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2010-02-16 | — | — | US | disclosed |
| US-20050043544-A1 | Process for producing fused imidazole compound, reformatsky reagent in stable form, and process for producing the same | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2005-02-24 | — | — | US | disclosed |
| EP-1471056-A1 | PROCESS FOR PRODUCING FUSED IMIDAZOLE COMPOUND, REFORMATSKY REAGENT IN STABLE FORM, AND PROCESS FOR PRODUCING THE SAME | Takeda Chemical Industries, Ltd. (JP) | 2004-10-27 | — | — | EP | disclosed |
| US-4690157-A | DERIVATIVES OF BUTYROLACTONE OR VALEROLACTONE; CIGARETTES | PHILIP MORRIS INCORPORATED (US) | 1987-09-01 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120077985-A1 | PROCESS FOR PRODUCING FUSED IMIDAZOLE COMPOUND, REFORMATSKY REAGENT IN STABLE FORM, AND PROCESS FOR PRODUCING THE SAME | CYP17A1, HSD17B7, HSD17B1 | LMNA 4293/4885MEN1 389/4885CYP2D6 731/4885 |
| US-20050043544-A1 | Process for producing fused imidazole compound, reformatsky reagent in stable form, and process for producing the same | CYP17A1, HSD17B7, HSD17B1 | LMNA 4296/4885MEN1 375/4885CYP2D6 724/4885 |
| US-20100105922-A1 | PROCESS FOR PRODUCING FUSED IMIDAZOLE COMPOUND, REFORMATSKY REAGENT IN STABLE FORM, AND PROCESS FOR PRODUCING THE SAME | CYP17A1, HSD17B7, HSD17B1 | LMNA 4293/4885MEN1 389/4885CYP2D6 731/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.